Takes over Regulatory Literature Monitoring Services from Springer Nature
New York, USA and Bangalore, India – December 15, 2021: Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, has introduced regulatory literature monitoring for pharmaceutical organizations by entering a managed services engagement with Springer Nature.
Drug safety, referred to as Pharmacovigilance (PV), constitutes the detection, collection, prevention, and monitoring of negative effects that may occur because of the use of pharmaceutical products and other drugs. PV departments in Life Sciences organizations, to fulfil drug safety requirements, leverage literature monitoring that includes Annual Reports, Periodic Safety Update Reports, Individual Case Study Report (ICSR) Monitoring, among others.
Matthias Wissel, CEO, Springer Nature Technology and Publishing Solutions, said, “The pharmacovigilance industry has been rapidly growing over the years and the recent COVID-19 pandemic and vaccine development efforts have only augmented the need for more efficient pharmacovigilance practices. I am confident that the transition of our ADIS Pharmacovigilance business to Wipro Limited will enhance their collective capabilities and provide colleagues with new opportunities. Additionally, Wipro’s domain expertise and investment in innovative and progressive platforms, such as TaloSafe and other new technologies, will further strengthen customer relationships, both existing and new.”
Krishna Nacha, Senior Vice President, Head of Global Business Services and Enterprise Transformation, iCORE, Wipro Ltd., said, “Over the past 18 months, increased patient safety has become paramount the world over. Organisations working with Wipro, a leader in the PV space, will benefit from ICSR literature services that have been developed over 15 years to a client base that includes 19 global Life Sciences companies.”
TaloSafe enables organizations to automate end-to-end PV processes and represents expertise developed by Wipro in the Life Sciences space over the past decade.
About Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading global information technology, consulting and business process services company. We harness the power of cognitive computing, hyper-automation, robotics, cloud, analytics and emerging technologies to help our clients adapt to the digital world and make them successful. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability and good corporate citizenship, we have over 220,000 dedicated employees serving clients across six continents. Together, we discover ideas and connect the dots to build a better and a bold new future.
Sandeep Deb Varman
The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.